We want to be your partner and drive pioneering therapies to the market. We invest in enabling technologies and build expertise to support the development and commercialization of your new innovative therapy. Our scientists and engineers bring decade-long development experience across a broad spectrum of cell types and technologies. This builds the backbone of an extensive service offering… Read More
BIA Separations has 20 years’ experience in chromatographic purification. Our products, CIM monoliths, were designed with unique operating properties that make them ideally suited to the challenging requirements of purifying biomolecules such as virus particles, vesicles, proteins, RNA’s, plasmids and other forms of DNA. We provide products that range from small analytical columns to large industrial prep-scale columns (including cGMP and disposable units) as well as method development services.
Brammer Bio is dedicated to providing clinical and commercial viral vectors for in vivo gene and ex vivo gene-modified cell therapies, from process and analytical development through commercial approval. We have a highly skilled team of scientists with expertise from over 100 client projects to tackle the challenges posed by these novel technologies and help accelerate their transition from the clinic to patients, while focusing on meeting cGMP standards. Brammer Bio is Helping to Cure.®
QPS is a global, science driven, customer-focused CRO that provides preclinical studies and clinical trials to the biotech and pharmaceutical industries. Our 1100+ person organization has expertise in nearly all drug modalities including small molecules, proteins, and other biotherapeutics. We have supported gene therapy since 2002: ASOs, siRNAs, miRNA through mRNAs and viral vectors. Our bioanalytical technologies include LC-HRMS, hybridization-LC, and qPCR; while our full spectrum DMPK services covers PK, DDI, biodistribution, and radiolabel studies.
Rho, a contract research organization (CRO) located in Chapel Hill, NC, provides a full range of services across the entire drug development process. For more than 30 years, Rho has been a trusted partner to leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, innovative technologies, and therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.
Patients First – it’s in our DNA. At CareMetx, we fight for every patient “from intake to outcomes” by providing Hub/reimbursement services, leading-class technology and strategic consulting to accelerate access to life-saving treatments. Speed and efficiency – is why we’re different. CareMetx leverages our expertise and innovative patient eAccess technology to revolutionize the patient experience. We partner with our clients to launch or transition pharmaceutical programs in record time with significant cost savings.
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon aims to build strong client partnerships with the world’s best biotech and pharma companies, focusing on transformative technologies, including gene therapies, next-generation vaccines, oncology immunotherapies, therapeutic proteins, and other complex biologics.
Vigene Biosciences’ mission is to Make Gene Therapy Affordable. Headquartered in Rockville, MD, Vigene offers FDA and EMA compliant cGMP production for AAV, lentivirus, adenovirus. With a proven record of cGMP grade AAV, lentivirus and adenovirus production, Vigene is combining the proven production technologies with rigorous regulatory compliant cGMP production to meet the needs and expectations of clinical material clients. [Read More]
Diamond Pharma Services is a leading European technical and scientific consulting group with deep expertise in gene therapies. Diamond are proud to have supported the regulatory approval of the first gene therapy product in Europe (Glybera), and continue to work on a broad portfolio of gene, and gene modified cell therapies. Our specialised team has broad and varied industry experience offering both breadth and depth of expertise, from which our clients can benefit.